Mike Romanos wins promotion

Becomes chief executive of Crescendo Biologics

Crescendo Biologics has appointed Mike Romanos as chief executive.

Romanos has been chief scientific officer of the Cambridge, UK-based company since May 2009 and has led its formation and the development of its proprietary antibody fragment technologies.

Since 2009 Crescendo has established a colony of engineered mice completely devoid of endogenous antibody polypeptides. These ‘triple knockout’ mice are believed to be unique and have the immunoglobulin heavy chain (IgH), kappa light chain and lambda light chain loci all functionally silenced by large-scale genomic deletion.

Romanos has more than 23 years’ biotech and pharma industry experience and within the last 10 years has held senior global positions leading major parts of GlaxoSmithKline Discovery.

You may also like

Research & Development

Crescendo Biologics announces cancer research collaboration

Dr Andrew Pierce, VP Translational Biology at Crescendo, said: “The ICR is a world-renowned research institution, and we are very excited to have the opportunity to collaborate with Professor de Bono and his team"
Research & Development

Crescendo Biologics reaches first major milestone in strategic collaboration with Takeda

Crescendo, the developer of multifunctional biologics, including targeted T-cell engagers, has achieved the first major technical milestone under the terms of its collaboration with Takeda Pharmaceutical Company
Research & Development

Crescendo Biologics expands ADC programmes with Innovate UK grant

Award will support development of new therapies to target prostate cancer
Research & Development

Multi million pound seed funding enables Crescendo Biologics to advance fragment antibody technology

<p>Crescendo Biologics has raised £4.5m in a seed funding round
Research & Development

Dual inhibition of motor proteins KIF18A and CENP-E shown to selectively kill cancer cells

Researchers from Osaka University and MIT have discovered that blocking two cooperative motor proteins involved in chromosome alignment can trigger cancer cell death, revealing a promising new target for anticancer therapies
Research & Development

EVerZom and GENFIT partner for research collaboration for liver failure candidate EViv

The agreement will support EVerZom’s dynamic development strategy and follows the recent announcement of a €10m financing round aimed at accelerating its clinical and partnering roadmap
Research & Development

Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development

Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies
Subscribe now